Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE ISSUED BY DARA BIOSCIENCES, INC. ON JUNE 16, 2014 - Midatech Pharma US Inc. | dara_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 12, 2014
DARA BioSciences, Inc.
(Exact name of registrant as specified in charter)
Delaware
|
0-19410
|
04-3216862
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
file number)
|
(IRS Employer
Identification Number)
|
8601 Six Forks Road, Suite 160, Raleigh, North Carolina
|
27615
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: 919-872-5578
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On June 16, 2014, DARA BioSciences, Inc, (the “Company”) reported that on June 12, 2014, the U.S. Food and Drug Administration granted Orphan Drug Designation to KRN5500 for treatment of multiple myeloma. KRN5500 is a novel, non-opioid, non-narcotic intravenous product currently in Phase 2 clinical development which also received Orphan Drug Designation in February 2014 for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics.
On June 16, 2014, the Company issued a press release, a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K.
.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description
|
|
99.1
|
Press Release issued by DARA BioSciences, Inc. on June 16, 2014
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DARA BioSciences, Inc.
|
|||
Dated: June 16, 2014
|
By:
|
/s/ David J. Drutz
|
|
Name: David J. Drutz
|
|||
Title: Chief Executive Officer
|
|||